Fluorometric Measurement of Suprabasal Cytokeratins and DNA of Human Keratinocytes Cultivated in Microtiter Plates

Görmar, F. E.; Theilig, C.; Dold, Karen M.; Bernd, August; Holzmann, H.

doi:10.1007/978-3-642-77817-9_14

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in vivo, GC‐induced effects on collagen metabolism are delayed and represent an end point of GC‐induced skin damage (7,10). In vitro , varying effects of GC on collagen expression have been reported depending on concentration and cell culture conditions (19–22). Not surprisingly, we did not observe a GC‐induced downregulation of COL1 and COL3 mRNA using our 120 h protocol.…”

Section: Discussionmentioning

confidence: 99%

Suppression of hyaluronan synthase 2 expression reflects the atrophogenic potential of glucocorticoids

Averbeck

Gebhardt

Anderegg

et al. 2010

Experimental Dermatology

View full text Add to dashboard Cite

We recently demonstrated that dexamethasone, a strongly atrophogenic glucocorticoid (GC), downregulated hyaluronan (HA) production in human keratinocytes and fibroblasts in vitro and after topical application to human skin in vivo via suppression of hyaluronan synthase 2 (HAS2). To test whether HAS2 activity might discriminate the atrophogenic potential of other substances applied topically to skin, we compared the HA metabolism in cultured human fibroblasts following in vitro treatment with GCs and the non-atrophogenic calcineurin inhibitor tacrolimus. GCs suppressed HAS2 mRNA expression and decreased HA as shown by qRT-PCR or ELISA.Tacrolimus did not affect hyaluronan-metabolizing enzymes nor total HA. Neither mometasone nor tacrolimus affected the expression of collagen mRNAs in human fibroblasts. In conclusion, suppression of HAS2 activity may represent an early process of GC-induced skin atrophy that precedes the suppression of collagens. Analysis of HAS2 regulation may thus be of value to assess the atrophogenic potential of drugs being developed.

show abstract

Section: Discussionmentioning

confidence: 99%